Department of Immunobiology, Yale School of Medicine, New Haven, CT, United States.
Department of Dermatology, Yale School of Medicine, New Haven, CT, United States.
Int Rev Cell Mol Biol. 2019;342:1-25. doi: 10.1016/bs.ircmb.2018.07.003. Epub 2018 Aug 20.
Elimination of cancer cells through antitumor immunity has been a long-sought after goal since Sir F. Macfarlane Burnet postulated the theory of immune surveillance against tumors in the 1950s. Finally, the use of immunotherapeutics against established cancer is becoming a reality in the past 5years. Most notable are the monoclonal antibodies (mAbs) directed against inhibitory T-cell receptors cytotoxic T lymphocyte antigen-4 and programmed death-1. The next generation of mAbs targeting T cells is designed to stimulate costimulatory receptors on T cells. Here we review the recent progress on these immunostimulatory agonist antibodies against the costimulatory receptors CD137, GITR, OX40, and CD27.
自 20 世纪 50 年代弗雷德·麦克法兰·伯内特爵士提出肿瘤免疫监视理论以来，通过抗肿瘤免疫消除癌细胞一直是人们梦寐以求的目标。终于，在过去的 5 年中，针对已确立的癌症的免疫疗法开始成为现实。最值得注意的是针对抑制性 T 细胞受体细胞毒性 T 淋巴细胞抗原-4 和程序性死亡受体-1 的单克隆抗体（mAb）。针对 T 细胞的下一代 mAb 旨在刺激 T 细胞上的共刺激受体。在这里，我们回顾了针对共刺激受体 CD137、GITR、OX40 和 CD27 的这些免疫刺激激动剂抗体的最新进展。
